



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

- 2 WHO. Virtual press conference on COVID-19—11 March 2020. March 11, 2020. https://www.who.int/docs/default-source/coronavirus/transcripts/who-audio-emergencies-coronavirus-press-conference-full-and-final-11mar2020.pdf?sfvrsn=cb432bb3_2 (accessed March 20, 2020).
- 3 Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? *Lancet* 2020; published online March 13. [https://doi.org/10.1016/S0140-6736\(20\)30627-9](https://doi.org/10.1016/S0140-6736(20)30627-9).
- 4 Government of Italy. Decree of the president of the Council of Ministers 9 March 2020. March 9, 2020. <https://www.gazzettaufficiale.it/eli/id/2020/03/09/20A01558/sg> (accessed March 20, 2020; in Italian).
- 5 Government of Italy. Decree of the president of the Council of Ministers 11 March 2020. March 11, 2020. <https://www.gazzettaufficiale.it/eli/id/2020/03/11/20A01605/sg> (accessed March 20, 2020; in Italian).
- 6 Biondi-Zoccai G, Landoni G, Carnevale R, Cavarretta E, Sciarretta S, Frati G. SARS-CoV-2 and COVID-19: facing the pandemic together as citizens and cardiovascular practitioners. *Minerva Cardioangiol* 2020; published online March 9. DOI:10.23736/S0026-4725.20.05250-0.

Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?

Mehta and colleagues¹ postulate that hyperinflammation in coronavirus disease 2019 (COVID-19) could be a driver of severity that is amenable to therapeutic targeting since retrospective data have shown that systemic inflammation is associated with adverse outcome. However, correlation does not equal causation, and it is equally plausible that increased virus burden (secondary to failure of the immune response to control infection) drives inflammation and consequent severity (as shown for other viruses²) rather than augmented inflammation being an inappropriate host response that requires correction.

The authors hypothesise that approaches such as corticosteroids or Janus kinase (JAK) inhibitors could be considered if hyperinflammation is present.¹ Broad immunosuppression in patients with overwhelming viral illness might be inadvisable. Beneficial anti-inflammatory effects should be weighed up against the potentially

detrimental effects of inhibiting antiviral immunity, thereby delaying virus clearance and perpetuating illness. Accordingly, findings from multiple studies in humans and animals indicate that corticosteroid immunosuppression (both inhaled and systemic) impairs induction of anti-viral type-I interferon responses to a range of respiratory viruses,^{3,4} effects that are likely to also occur in the context of COVID-19. Selective therapies with JAK inhibitors could be expected to have similar effects. JAK-STAT signalling is a major component of the type-I interferon pathway.³ Tofacitinib has been shown to inhibit interferon- α production *in vitro*.⁵ Suppression of interferon or other mediators (eg, interleukin 6) could also promote secondary bacterial infection and further complicate the disease course.³

The decision to pharmacologically immunosuppress a critically unwell patient with COVID-19 remains a difficult one. Possible beneficial effects of reducing inflammation should be carefully weighed up against the potential for deleterious impairment of anti-microbial immunity.

AS reports personal fees for consultancy from AstraZeneca and funds from grants from the Wellcome Trust, the British Lung Foundation, and others, all unrelated to this Correspondence. AIR declares no competing interests.

Andrew I Ritchie, *Aran Singanayagam
a.singanayagam@imperial.ac.uk

National Heart and Lung Institute, Imperial College London, London SW7 2AZ, UK (AIR, AS); and Royal Brompton and Harefield NHS Trust, London, UK (AS)

- 1 Mehta PM, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet* 2020; published online March 16. [https://doi.org/10.1016/S0140-6736\(20\)30628-0](https://doi.org/10.1016/S0140-6736(20)30628-0).
- 2 Lee N, Chan MC, Lui GC, et al. High viral load and respiratory failure in adults hospitalized for respiratory syncytial virus infections. *J Infect Dis* 2015; **212**: 1237–40.
- 3 Singanayagam A, Glanville N, Girkin JL, et al. Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations. *Nat Commun* 2018; **9**: 2229.
- 4 Thomas BJ, Porritt RA, Hertzog PJ, Bardin PG, Tate MD. Glucocorticosteroids enhance replication of respiratory viruses: effect of adjuvant interferon. *Sci Rep* 2014; **4**: 7176.

- 5 Boor PPC, de Ruiter PE, Asmawidjaja PS, Lubberts E, van der Laan LJW, Kwekkeboom J. JAK-inhibitor tofacitinib suppresses interferon alfa production by plasmacytoid dendritic cells and inhibits arthrogenic and antiviral effects of interferon alfa. *Transl Res* 2017; **188**: 67–79.

Authoritarianism and the threat of infectious diseases

Punitive social policy, encompassing the dismantling of the welfare state and the expansion of the penal state and its associated institutions, as nicely stated by Elias Nosrati and Michael Marmot in their Perspective,¹ might indeed be considered an upstream social determinant of health. Nosrati and Marmot's analysis relates to the findings described by Navarro and colleagues,² linking political ideology with policies aimed at reducing social inequalities such as welfare state and labour market policies.

The increasingly punitive policy environment in North America, Europe, and some South American countries (eg, Brazil and Argentina) is probably related to the spread of an authoritarian ideology that has xenophobia at its core.

However, a trait of those repulsion speeches that is often missed is how immigrants or strangers are referred to as parasites or contagious agents. Recent examples include the xenophobic and, in some cases violent, acts committed against Asiatic citizens in Western countries since the coronavirus disease 2019 outbreak began,³ or Donald Trump's statement that "tremendous" infectious disease is pouring across the Mexican border into the USA.⁴ Constant upheavals by the Trump and Orbán⁵ administrations about migrants, some of Brexit's collateral effects,⁶ and statements about refugees by the Italian politician Matteo Salvini⁷ and the Spanish far-right Vox party⁸ can be understood in this context.

It is not that foreigners cannot transmit threatening infectious



Published Online
March 23, 2020
[https://doi.org/10.1016/S0140-6736\(20\)30691-7](https://doi.org/10.1016/S0140-6736(20)30691-7)